Nadejda Valiaeva • UCSD Profiles (original) (raw)

  1. Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. Antimicrob Agents Chemother. 2024 10 08; 68(10):e0103924. Carlin AF, Beadle JR, Ardanuy J, Clark AE, Rhodes V, Garretson AF, Murphy JA, Valiaeva N, Schooley RT, Frieman MB, Hostetler KY. PMID: 39240093; PMCID: PMC11459966.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansAnimalsCells
  2. Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs. Antiviral Res. 2023 11; 219:105718. McMillan RE, Lo MK, Zhang XQ, Beadle JR, Valiaeva N, Garretson AF, Clark AE, Freshman JE, Murphy J, Montgomery JM, Spiropoulou CF, Schooley RT, Hostetler KY, Carlin AF. PMID: 37758067; PMCID: PMC10790242.
    View in: PubMed Mentions: 4 Fields:
  3. 1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity. J Med Chem. 2023 04 27; 66(8):5802-5819. Carlin AF, Beadle JR, Clark AE, Gully KL, Moreira FR, Baric RS, Graham RL, Valiaeva N, Leibel SL, Bray W, McMillan RE, Freshman JE, Garretson AF, McVicar RN, Rana T, Zhang XQ, Murphy JA, Schooley RT, Hostetler KY. PMID: 37040439; PMCID: PMC10108740.
    View in: PubMed Mentions: 5 Fields:
    Translation:AnimalsCells
  4. Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524). Microbiol Spectr. 2021 12 22; 9(3):e0153721. Lo MK, Shrivastava-Ranjan P, Chatterjee P, Flint M, Beadle JR, Valiaeva N, Murphy J, Schooley RT, Hostetler KY, Montgomery JM, Spiropoulou CF. PMID: 34817209; PMCID: PMC8612139.
    View in: PubMed Mentions: 23 Fields:
    Translation:HumansAnimalsCells
  5. Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524). bioRxiv. 2021 Aug 10. Lo MK, Shrivastava-Ranjan P, Chatterjee P, Flint M, Beadle JR, Valiaeva N, Schooley RT, Hostetler KY, Montgomery JM, Spiropoulou C. PMID: 34401879; PMCID: PMC8366795.
    View in: PubMed Mentions:
  6. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0115521. Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY. PMID: 34310217; PMCID: PMC8448143.
    View in: PubMed Mentions: 45 Fields:
    Translation:HumansAnimalsCells
  7. Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs. bioRxiv. 2021 Jun 07. Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY. PMID: 32869033; PMCID: PMC7457622.
    View in: PubMed Mentions: 1
  8. Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate. Antiviral Res. 2019 11; 171:104614. Beadle JR, Aldern KA, Zhang XQ, Valiaeva N, Hostetler KY, Schooley RT. PMID: 31550449; PMCID: PMC6927535.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCells
  9. Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro. Antiviral Res. 2018 10; 158:122-126. Kumaki Y, Woolcott JD, Roth JP, Mclean TZ, Smee DF, Barnard DL, Valiaeva N, Beadle JR, Hostetler KY. PMID: 30096340.
    View in: PubMed Mentions: Fields:
    Translation:HumansCellsPHPublic Health
  10. Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. J Med Chem. 2016 12 08; 59(23):10470-10478. Beadle JR, Valiaeva N, Yang G, Yu JH, Broker TR, Aldern KA, Harden EA, Keith KA, Prichard MN, Hartman T, Buckheit RW, Chow LT, Hostetler KY. PMID: 27933957.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  11. A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy. Mol Vis. 2012; 18:1907-17. Kim JS, Beadle JR, Freeman WR, Hostetler KY, Hartmann K, Valiaeva N, Kozak I, Conner L, Trahan J, Aldern KA, Cheng L. PMID: 22876115; PMCID: PMC3413433.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansAnimalsCells
  12. Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action. Antimicrob Agents Chemother. 2011 Nov; 55(11):5063-72. Magee WC, Valiaeva N, Beadle JR, Richman DD, Hostetler KY, Evans DH. PMID: 21896914; PMCID: PMC3195056.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCells
  13. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem. 2011 Aug 01; 19(15):4616-25. Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. PMID: 21719300; PMCID: PMC3139790.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  14. Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation. Mol Vis. 2011 Mar 02; 17:627-37. Hou J, Li Y, Zhou Z, Valiaeva N, Beadle JR, Hostetler K, Freeman WR, Hu DN, Chen H, Cheng L. PMID: 21386925; PMCID: PMC3049735.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  15. Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo. Chemotherapy. 2010; 56(1):54-9. Valiaeva N, Trahan J, Aldern KA, Beadle JR, Hostetler KY. PMID: 20215748; PMCID: PMC2914419.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansAnimalsCells
  16. Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Res. 2009 Dec; 84(3):254-9. Valiaeva N, Prichard MN, Buller RM, Beadle JR, Hartline CB, Keith KA, Schriewer J, Trahan J, Hostetler KY. PMID: 19800369; PMCID: PMC2787864.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansAnimalsCells
  17. Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob Agents Chemother. 2009 Dec; 53(12):5284-7. Botros SS, William S, Beadle JR, Valiaeva N, Hostetler KY. PMID: 19704122; PMCID: PMC2786359.
    View in: PubMed Mentions: 5 Fields:
    Translation:AnimalsCells
  18. Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. Antimicrob Agents Chemother. 2008 Dec; 52(12):4326-30. Prichard MN, Hartline CB, Harden EA, Daily SL, Beadle JR, Valiaeva N, Kern ER, Hostetler KY. PMID: 18852272; PMCID: PMC2592848.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  19. Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro. Antiviral Res. 2006 Oct; 72(1):10-9. Valiaeva N, Beadle JR, Aldern KA, Trahan J, Hostetler KY. PMID: 16630664.
    View in: PubMed Mentions: 13 Fields:
    Translation:HumansCells
  20. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 2005 Feb; 49(2):656-62. Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY. PMID: 15673748; PMCID: PMC547274.
    View in: PubMed Mentions: 33 Fields:
    Translation:HumansAnimalsCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs